Opin vísindi

Fletta eftir höfundi "Glintborg, Bente"

Fletta eftir höfundi "Glintborg, Bente"

Röðun: Raða: Niðurstöður:

  • Icon
    Correction to : Correction to: Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration (Rheumatology (Oxford, England) (2022) 61 11 (4286-4296)) 
    Delcoigne, Bénédicte; Provan, Sella Aarrestad; Hammer, Hilde Berner; Di Giuseppe, Daniela; Frisell, Thomas; Glintborg, Bente; Grondal, Gerdur; Gudbjornsson, Bjorn; Hetland, Merete Lund; Michelsen, Brigitte; Nordström, Dan; Relas, Heikki; Askling, Johan (2022-03-25)
  • Icon
    Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe 
    Michelsen, Brigitte; Østergaard, Mikkel; Nissen, Michael John; Ciurea, Adrian; Möller, Burkhard; Ørnbjerg, Lykke Midtbøll; Zavada, Jakub; Glintborg, Bente; MacDonald, Alan; Laas, Karin; Nordström, Dan; Guðbjörnsson, Björn; Iannone, Florenzo; Hellmand, Pasoon; Kvien, Tore Kristian; Rodrigues, Ana Maria; Codreanu, Catalin; Rotar, Ziga; Castrejón Fernández, Isabel; Wallman, Johan Karlsson; Vencovsky, Jiri; Loft, Anne Gitte; Heddle, Maureen; Vorobjov, Sigrid; Hokkanen, Anna Mari; Gröndal, Gerður María; Sebastiani, Marco; van de Sande, Marleen; Kristianslund, Eirik Klami; Santos, Maria José; Mogosan, Corina; Tomsic, Matija; Díaz-González, Federico; Di Giuseppe, Daniela; Hetland, Merete Lund (2023-10)
    This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed ...
  • Icon
    Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? : Results from a Nordic collaboration 
    Delcoigne, Bénédicte; Provan, Sella Aarrestad; Hammer, Hilde Berner; Di Giuseppe, Daniela; Frisell, Thomas; Glintborg, Bente; Grondal, Gerdur; Gudbjornson, Bjorn; Hetland, Merete Lund; Michelsen, Brigitte; Nordström, Dan; Relas, Heikki; Askling, Johan (2022-02-09)
    OBJECTIVES: To investigate whether patient-reported outcomes vary across countries and are influenced by cultural/contextual factors. Specifically, we aimed to assess inter-country differences in tender joint count (TJC), pain and patient's global ...
  • Icon
    Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration 
    Lindström, Ulf; Di Giuseppe, Daniela; Delcoigne, Bénédicte; Glintborg, Bente; Möller, Burkhard; Ciurea, Adrian; Pombo-Suarez, Manuel; Sanchez-Piedra, Carlos; Eklund, Kari; Relas, Heikki; Guðbjörnsson, Björn; Löve, Þorvarður Jón; Jones, Gareth T.; Codreanu, Catalin; Ionescu, Ruxandra; Nekvindova, Lucie; Závada, Jakub; Atas, Nuh; Yolbas, Servet; Fagerli, Karen Minde; Michelsen, Brigitte; Rotar, Ziga; Tomšič, Matija; Iannone, Florenzo; Santos, Maria Jose; Avila-Ribeiro, Pedro; Ørnbjerg, Lykke Midtbøll; Østergaard, Mikkel; Jacobsson, Lennart T.H.; Askling, Johan; Nissen, Michael J. (2021-06-03)
    Background Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains ...
  • Icon
    How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers 
    Chatzidionysiou, Katerina; Delcoigne, Bénédicte; Frisell, Thomas; Hetland, Merete L; Glintborg, Bente; dreyer, lene; Cordtz, René; Zobbe, Kristian; Nordström, Dan; Trokovic, Nina; Aaltonen, Kalle; Provan, Sella Aarrestad; Gröndal, Gerður; Gudbjornsson, Bjorn; Askling, Johan (BMJ, 2020-09-08)
    [No abstract available]
  • Icon
    Is the risk of infection higher during treatment with secukinumab than with TNF-inhibitors? : An observational study from the Nordic countries 
    Glintborg, Bente; Di Giuseppe, Daniela; Wallman, Johan K; Provan, Sella A; Nordström, Dan; Hokkanen, Anna-Mari; Österlund, Jenny; Kristianslund, Eirik; Kvien, Tore K; Guðbjörnsson, Björn; Hetland, Merete Lund; Michelsen, Brigitte; Jacobsson, Lennart; Askling, Johan; Lindström, Ulf (2022-06-20)
    OBJECTIVES: The positioning of secukinumab in the treatment of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) is debated, partly due to a limited understanding of the comparative safety of available treatments. We aimed to assess risk ...
  • Icon
    Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration 
    Ørnbjerg, Lykke Midtbøll; Linde, Louise; Georgiadis, Stylianos; Horskjær Rasmussen, Simon; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Di Giuseppe, Daniela; Wallman, Johan K.; Pavelka, Karel; Závada, Jakub; Nissen, Michael J; Jones, Gareth T.; Relas, Heikki; Pirilä, Laura; Tomšič, Matija; Rotar, Ziga; Geirsson, Árni Jón; Guðbjörnsson, Björn; Kristianslund, Eirik K.; van sder Horst-Bruinsma, Irene; Loft, Anne Gitte; Laas, Karin; Iannone, Florenzo; Corrado, Addolorata; Ciurea, Adrian; Santos, Maria José; Santos, Helena; Codreanu, Catalin; Akkoc, Nurullah; Gunduz, Ozgul S.; Glintborg, Bente; Østergaard, Mikkel; Lund Hetland, Merete (2022-10-01)
    Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive ...
  • Icon
    Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor : results from 13 European registries 
    Linde, Louise; Ørnbjerg, Lykke M; Georgiadis, Stylianos; Rasmussen, Simon H; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Di Giuseppe, Daniela; Wallman, Johan K; Guðbjörnsson, Björn; Löve, Þorvarður Jón; Nordström, Dan C; Yli-Kerttula, Timo; Nekvindová, Lucie; Vencovský, Jiří; Iannone, Florenzo; Cauli, Alberto; Loft, Anne Gitte; Glintborg, Bente; Laas, Karin; Rotar, Ziga; Tomšič, Matija; Macfarlane, Gary J; Möller, Burkhard; van de Sande, Marleen; Codreanu, Catalin; Nissen, Michael J; Birlik, Merih; Erten, Sukran; Santos, Maria J; Vieira-Sousa, Elsa; Hetland, Merete L; Østergaard, Mikkel (2023-06-14)
    OBJECTIVES: In bio-naïve patients with Psoriatic arthritis (PsA) initiating a Tumour Necrosis Factor inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and ...
  • Icon
    Second and third TNF inhibitors in European patients with axial spondyloarthritis : Effectiveness and impact of the reason for switching 
    Linde, Louise; Ørnbjerg, Lykke Midtbøll; Brahe, Cecilie Heegaard; Wallman, Johan Karlsson; Di Giuseppe, Daniela; Závada, Jakub; Castrejon, Isabel; Díaz-Gonzalez, Federico; Rotar, Ziga; Tomšič, Matija; Glintborg, Bente; Guðbjörnsson, Björn; Geirsson, Árni Jón; Michelsen, Brigitte; Kristianslund, Eirik Klami; Santos, Maria José; Barcelos, Anabela; Nordström, Dan; Eklund, Kari K; Ciurea, Adrian; Nissen, Michael; Akar, Servet; Hyldstrup, Lise Hejl; Krogh, Niels Steen; Hetland, Merete Lund; Østergaard, Mikkel (2023-09-20)
    OBJECTIVE: To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with 1) treatment line (second and third TNFi-series) and 2) reason for withdrawal from ...
  • Icon
    Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis : Results from the EuroSpA Research Collaboration Network 
    Hellamand, Pasoon; Van De Sande, Marleen; Ørnbjerg, Lykke Midtbøll; Klausch, Thomas; Nurmohamed, Michael T.; Van Vollenhoven, Ronald F.; Nordström, Dan; Hokkanen, Anna Mari; Santos, Maria Jose; Vieira-Sousa, Elsa; Loft, Anne G.; Glintborg, Bente; Hetland, Merete Lund; Lindström, Ulf; Wallman, Johan K.; Michelsen, Brigitte; Klami Kristianslund, Eirik; Ciurea, Adrian; Nissen, Michael S.; Codreanu, Catalin; Mogosan, Corina; Macfarlane, Gary J.; Rotariu, Ovidiu; Rotar, Ziga; Tomšič, Matija; Castrejon, Isabel; Otero-Varela, Lucia; Guðbjörnsson, Björn; Geirsson, Árni Jón; Vencovský, Ji; Pavelka, Karel; Gulle, Semih; Zengin, Berrin; Iannone, Florenzo; Foti, Rosario; Ostergaard, Mikkel; Van Der Horst-Bruinsma, Irene (2023-12-12)
    Objective Evidence indicates reduced treatment effectiveness of TNFi in women with axial spondyloarthritis (axSpA) compared with men. We aimed to investigate sex differences in treatment response and retention rates over 24 months of follow-up in axSpA ...
  • Icon
    Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs : results from four Nordic countries 
    Delcoigne, Benedicte; Ljung, Lotta; Provan, Sella A; Glintborg, Bente; Hetland, Merete Lund; Grøn, Kathrine Lederballe; Peltomaa, Ritva; Relas, Heikki; Turesson, Carl; Guðbjörnsson, Björn; Michelsen, Brigitte; Askling, Johan (2022-03-22)
    OBJECTIVES: To compare the 1-year, 2-year and 5-year incidences of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) starting any of the biologic disease-modifying antirheumatic drugs (bDMARDs) currently available in clinical ...
  • Icon
    Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis 
    Lindström, Ulf; Glintborg, Bente; Di Giuseppe, Daniela; Nordström, Dan; Aarrestad Provan, Sella; Gudbjornsson, Bjorn; Askling, Johan; Hetland, Merete Lund; Aaltonen, Kalle; Krogh, Niels Steen; Geirsson, Árni J.; Jacobsson, Lennart (BMJ, 2019-10)
    Objective Although clinical trials support equivalence of originator products and biosimilars for etanercept and infliximab, real-world studies among biologics-naïve patients with spondyloarthritis (SpA) are lacking. The objectives were to compare ...